Pharsight

Actonel patents expiration

ACTONEL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7192938 APIL Method of treatment using bisphosphonic acid
May, 2023

(4 months ago)

US7718634 APIL Method of treatment using bisphosphonic acid
May, 2023

(4 months ago)

US7192938

(Pediatric)

APIL Method of treatment using bisphosphonic acid
Nov, 2023

(a month from now)

US7718634

(Pediatric)

APIL Method of treatment using bisphosphonic acid
Nov, 2023

(a month from now)

Actonel is owned by Apil.

Actonel contains Risedronate Sodium.

Actonel has a total of 4 drug patents out of which 2 drug patents have expired.

Expired drug patents of Actonel are:

  • US7192938
  • US7718634

Actonel was authorised for market use on 27 March, 1998.

Actonel is available in tablet;oral dosage forms.

Actonel can be used as prevention and treatment of osteoporosis, treatment of osteoporosis in postmenopausal women.

The generics of Actonel are possible to be released after 06 November, 2023.

Drugs and Companies using RISEDRONATE SODIUM ingredient

Market Authorisation Date: 27 March, 1998

Treatment: Prevention and treatment of osteoporosis; Treatment of osteoporosis in postmenopausal women

Dosage: TABLET;ORAL

How can I launch a generic of ACTONEL before it's drug patent expiration?
More Information on Dosage

ACTONEL family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic